Feng-shu Hsieh

TPQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Plausible, robust biological oscillations through allelic buffering.

Plausible, robust biological oscillations through allelic buffering.

Journal: Cell systems

Published: December 30, 2023

Enhanced DNA repair through droplet formation and p53 oscillations.

Enhanced DNA repair through droplet formation and p53 oscillations.

Journal: Cell

Published: April 13, 2022

Functional buffering via cell-specific gene expression promotes tissue homeostasis and cancer robustness.

Functional buffering via cell-specific gene expression promotes tissue homeostasis and cancer robustness.

Journal: Scientific reports

Published: August 25, 2021

Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation.

Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation.

Journal: Cell death & disease

Published: November 10, 2018

Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.

Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 09, 2018

Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].

Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112 (October) (2017) 81-89].

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 08, 2018

Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].

Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 24, 2018

Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation.

Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation.

Journal: The Journal of pharmacology and experimental therapeutics

Published: March 13, 2018

Corrigendum: Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma.

Corrigendum: Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma.

Journal: Scientific reports

Published: April 11, 2017

Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.

Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 04, 2017

Protein phosphatase 5 promotes hepatocarcinogenesis through interaction with AMP-activated protein kinase.

Protein phosphatase 5 promotes hepatocarcinogenesis through interaction with AMP-activated protein kinase.

Journal: Biochemical pharmacology

Published: January 26, 2017

Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.

Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.

Journal: Molecular oncology

Published: December 01, 2016

Showing 1-12 of 15

Last Updated: 09/26/2026